Floatz logo

Valoctocogene Roxaparvovec

Severe Haemophilia A

BioMarin Pharmaceuticalgene_therapyPhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

10 Active assets in the Severe Haemophilia A cohort.

Asset / SponsorPhaseRating
HUMAN ANTIHEMOPHILIC FACTOR/VON WILLEBRAND FACTOR COMPLEX
AryoGen Pharmed Co.
Phase 4BBB
Human-Cl Rhfviii
Octapharma
Phase 3BBB
Emicizumab
Chulalongkorn University
Phase 4BBB
Rfviiifc
Bioverativ Therapeutics Inc.
Phase 3BB
Frsw117
Hangzhou Gensciences Biopharmaceutical Co., Ltd.
Phase 3BB

View all 21 →

Same molecule, other indications

Valoctocogene Roxaparvovec is also rated in:

hemophilia ADormant
BB
Indicative ·
64 / 100
View asset →
blood coagulation diseaseDormant
CCC
Indicative ·
48 / 100
View asset →
hematologic disorderDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →